Cochrane Abstracts
Risperidone versus placebo for schizophrenia
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Risperidone Versus Placebo for Schizophrenia." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431736/all/Risperidone_versus_placebo_for_schizophrenia.
Risperidone versus placebo for schizophrenia. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431736/all/Risperidone_versus_placebo_for_schizophrenia. Accessed December 4, 2024.
Risperidone versus placebo for schizophrenia. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431736/all/Risperidone_versus_placebo_for_schizophrenia
Risperidone Versus Placebo for Schizophrenia [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 December 04]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431736/all/Risperidone_versus_placebo_for_schizophrenia.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Risperidone versus placebo for schizophrenia
ID - 431736
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431736/all/Risperidone_versus_placebo_for_schizophrenia
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
